Asx csl cut its FY26 guidance and flagged around $5 billion in additional asset impairments after a 90-day interim chief executive review. Gordon Naylor said the company’s growth initiatives are working, but the financial benefits will take longer than expected to materialise.
The update lands after CSL shares declined 49% over the past 12 months even as the S&P/ASX 200 Index rose 6% over the same period. For shareholders, the company is now pushing out the payoff from its turnaround work while absorbing a write-down large enough to reshape the near-term earnings path.
Naylor cuts FY26 outlook
Gordon Naylor said CSL revised down its 2026 financial year guidance and that the business has moved to a fresh view of how fast growth initiatives can feed through to profit. “Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise. As a result, we have now revised down our 2026 financial year guidance,” he said.
$5 billion in additional asset impairments sits at the center of the reset. That charge does not change the underlying demand story CSL is pointing to, but it does reduce the near-term earnings quality investors will measure against while management tries to rebuild momentum.
Behring and Seqirus split
CSL said its core business in plasma collection and influenza vaccines remains strong, with ongoing demand growth continuing in key markets. The company also said US Immunoglobulin and Albumin product segments are seeing stable or rising demand, while short-term revenue has been hit by price pressure and changes in market dynamics.
CSL Seqirus is tracking moderately ahead of earlier forecasts for the year and is anticipated to outperform previous forecasts. CSL also expects revenue growth in its CSL Behring division in the second half of FY26, which means the benefit from the broader reset is being pushed into later periods rather than showing up immediately.
$550 million savings by FY28
$500 million to $550 million in annual savings by FY28 is the target for CSL’s transformation and efficiency program. That gives the company a longer runway to offset the impairment charge and the weaker FY26 guide, but the savings still need time to flow through before they can support a cleaner earnings profile.
1 July 2026 marks the planned commercial leadership transition to Diego Sacristan, and CSL said a further update will come with full-year results in August 2026. Naylor said, “CSL's culture and people continue to be first class, the industry is stable and growing and the company has evident strengths in plasma collections and influenza vaccines.” He added, “I am confident that the company can be returned to profitable growth and my work is to position the business and the next CEO for success.”
